BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
5543- BBM,    Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo
- in-vivo, Lung, B16-F10 - vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-231
BioAv↓, Half-Life↓, eff↑, TumMeta↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, MMP2↓, MMP9↓, VEGF↓, Bcl-2↓, eff↑, EPR↑,
5591- BetA,    Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment
- Review, BC, NA
BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP/DDIT3↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,
5991- Chit,    Chitosan-Based Nanoencapsulated Essential Oils: Potential Leads against Breast Cancer Cells in Preclinical Studies
- Review, BC, NA
*other↝, *BioAv↓, eff↑, toxicity↓, eff↑, TumCD↑, Half-Life↑, selectivity↑, EPR↑, ROS↑, Apoptosis↑, eff↑,
4655- CUR,    Inhibition of Cancer Stem-like Cells by Curcumin and Other Polyphenol Derivatives in MDA-MB-231 TNBC Cells
- in-vitro, BC, NA
CSCs↓, *BioAv↓,
6801- EA,    A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury
- vitro+vivo, BC, 4T1
TumCCA↑, CDK4↓, RadioS↑, TumCG↓, *radioP↑, *cardioP↑, *antiOx↑, *ROS↓, Dose↑, selectivity↑, BioAv↓,
1608- EA,    Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF7 - in-vitro, Lung, A549 - in-vitro, Nor, HUVECs
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1 / PDPK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,
7044- GA,  QC,    Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity
- in-vitro, BC, MCF7
UGDH↓, UGDH↓, TumCP↓, Dose↑, *BioAv↓, eff?,
7468- HNK,    Honokiol and Its Emerging Role in Breast Cancer Therapy
- Review, BC, NA
*ROS↓, *Inflam↓, CSCs↓, ChemoSen↑, BioAv↑, ROS↑, MMP↓, mtDam↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓, BAX↑, p‑STAT3↓, AMPK↑, miR-34a↑, EMT↓, HH↓, Shh↓, Gli1↓, PTCH1↓, NF-kB↓, TNF-α↓, IL6↓, Glycolysis↓, GlucoseCon↓, BioAv↓, BioAv↓, Half-Life↝,
8081- KAE,    The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer
- Review, BC, NA
*antiOx↓, *Inflam↓, *neuroP↓, *AntiCan↑, DNAdam↓, Casp3↑, Casp9↑, p‑AMT/GCST/T-protein↑, ROS↑, NRF2↑, Apoptosis↑, cl‑PARP↓, BAX↑, Bcl-2↓, TumCCA↓, angioG↓, MMP3↓, MMP9↓, ChemoSen↑, BioAv↓, Glycolysis↓, cl‑PARP↑, Ca+2↑, MMP↓, ER Stress↑, GRP78/BiP↑, CHOP/DDIT3↑, ATF6↑, angioG↓, VEGF↓, Hif1a↓, chemoP↑, *ROS↓, NRF2↑, BioAv↑,
8166- LapC,    Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model
- vitro+vivo, BC, NA
BioAv↓, *toxicity↑, eff↑,
2910- LT,  FA,    Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment
- in-vitro, BC, 4T1 - in-vivo, NA, NA
BioAv↓, BioAv↑, eff↑, tumCV↓, e-H2O2↓, i-H2O2∅,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

p‑AMT/GCST/T-protein↑, 1,   UGDH↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

e-H2O2↓, 1,   i-H2O2∅, 1,   NRF2↑, 2,   ROS↑, 5,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MMP↓, 3,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 3,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 3,   Casp9↑, 3,   Cyt‑c↑, 1,   MAPK↑, 1,   MOMP↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 2,   ER Stress↑, 2,   GRP78/BiP?, 1,   GRP78/BiP↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

SESN2↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNAdam↑, 2,   cl‑PARP↓, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 2,   cycD1/CCND1↓, 1,   TumCCA↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 2,   EMT↓, 1,   Gli1↓, 1,   HH↓, 1,   miR-34a↑, 1,   mTOR⇅, 1,   PTCH1↓, 1,   PTEN↑, 1,   Shh↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   FAK↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 2,   TIMP2↑, 1,   TSC1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EPR↑, 2,   Hif1a↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 8,   BioAv↑, 4,   ChemoSen↑, 3,   Dose↑, 2,   Dose∅, 1,   eff?, 1,   eff↑, 9,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

E6↓, 1,   E7↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   toxicity↓, 1,  
Total Targets: 89

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 2,   ROS↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 1,   BioEnh↑, 1,   Half-Life∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   neuroP↓, 1,   radioP↑, 1,   toxicity↑, 1,  
Total Targets: 14

Scientific Paper Hit Count for: BioAv, bioavailability
2 Ellagic acid
1 Berbamine
1 Betulinic acid
1 chitosan
1 Curcumin
1 Gallic acid
1 Quercetin
1 Honokiol
1 Kaempferol
1 Lapachol
1 Luteolin
1 Folic Acid, Vit B9
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:792  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page